Data-driven stock analysis, valuation deep dives, and financial forensics. Every article backed by the numbers.
Keytruda revenue crossed $28 billion in 2025. The patent cliff arrives in 2028. The pipeline detail, the HIV expansion, and the ADC portfolio together suggest the revenue replacement math is already substantially solved.
RTX closed 2025 at $88.6 billion of revenue and $7.9 billion of free cash flow with a defence backlog north of $217 billion. Five charts explain why the forward multiple still understates the setup.
CAT's Energy & Transportation segment is now running at a $30 billion revenue pace on the back of data centre power demand. The market is still valuing the company as a pure construction cyclical.
Pfizer trades at 9.4x forward earnings with $9 billion of free cash flow and a 7% dividend yield. The consensus has priced a patent cliff apocalypse that the pipeline numbers do not actually support.
Net income at $30.5 billion for 2025 put BAC back near 2021 peak profitability. The forward multiple of 12.3x says the market is still pricing last cycle.
SLB reports this week after a year in which revenue dipped for the first time since 2020. The shape of Q1 is the tell for whether oilfield services has actually bottomed.
At $110 billion of market cap against $4.8 billion of revenue and a GAAP loss of $162 million, CrowdStrike is priced for a growth curve it has already stopped delivering. The maths gets brutal from here.
SoFi is a digital bank with an attached technology platform, not the reverse. The business mix dictates the multiple, not the marketing narrative.
Snowflake at 80x, Datadog at 59x, CrowdStrike at 88x. All three face decelerating revenue growth. The fair value gap to the current price is wider than the premium.
The capital allocation framework that Warren Buffett endorsed for 37 years has produced 5.8% per-share dividend growth compounded. The analytical take on whether the framework still fits.
Our 2024 piece argued the market was under-pricing the post-Humira ramp. Eighteen months later, the data supports the original view and extends the upside.
Keytruda loses US exclusivity in 2028. The pipeline covers half the $15-20 billion revenue hole. The replacement gap is what the multiple is discounting.
Five dimensions of comparison. Four favour Exxon. Capital efficiency, free cash flow, upstream growth, and balance sheet flexibility all point the same direction.
Revenue at $22.1 billion, FCF at $7.3 billion, reserves of 135 million ounces, and a 14x forward multiple. The Research Desk examines the valuation gap to peers.
Revenue is down 26% from peak, but operating margin has held at 17.5% thanks to the precision platform. The Research Desk examines whether the transition sustains the 33x multiple.